EGFR protein expression and overexpression are reported in 43% and 11% of gastric cancer patients, respectively [34], and EGFR overexpression is a significant predictor of poor survival in gastric cancer patients; however, a randomized phase III trial using cetuximab failed to show a significant improvement in patient survival [35]. The gene discussed is EGFR; the disease is gastric cancer.